EDGAR·FLOW

PMV Pharmaceuticals, Inc. — Form 8-K

Filed November 20, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
PMV Pharmaceuticals reported Phase 2 PYNNACLE trial data for rezatapopt (PC14586), a p53 reactivator targeting TP53 Y220C mutations: 48% confirmed ORR (31/65 patients) with 10.4-month median duration of response in platinum-resistant/refractory ovarian cancer; 36% ORR (61/168 patients) across all 168 evaluable patients in eight tumor types. Safety profile remained manageable with mostly Grade 1-2 adverse events; 6% (11/180) discontinued due to treatment-related adverse events. Company plans NDA submission for accelerated approval in Q1 2027.
Why this rating

Strong Phase 2 efficacy in targeted ovarian cancer cohort (48% ORR vs. limited alternatives for platinum-resistant disease) supports potential regulatory approval path. For $53.4M market-cap biotech, successful NDA approval could be transformational; however, approval is not guaranteed and clinical-stage risk remains high. Data is positive catalyst but company still pre-approval.

Price action (we called it positive)
before filing · preread
$0.87
at our read
pending
+10 min
pending
+30 min
pending
+1 hr
pending
+4 hrs
pending

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ PMVP · stock on Yahoo Finance ↗

See more from November 20, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.